Abstract
Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Current Drug Targets
Title: A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Volume: 7 Issue: 9
Author(s): U. Taksh
Affiliation:
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Abstract: Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Export Options
About this article
Cite this article as:
Taksh U., A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia, Current Drug Targets 2006; 7 (9) . https://dx.doi.org/10.2174/138945006778226589
DOI https://dx.doi.org/10.2174/138945006778226589 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Depressive Illness and Emotional Learning
Current Medical Imaging Advanced Magnetic Resonance Imaging Techniques in the Preterm Brain: Methods and Applications
Current Pediatric Reviews IRAK-4 Inhibitors for Inflammation
Current Topics in Medicinal Chemistry High-Resolution Structures of Large Ribosomal Subunits from Mesophilic Eubacteria and Halophilic Archaea at Various Functional States
Current Protein & Peptide Science Magnetic and Gold-Coated Magnetic Iron Oxide Nanoparticles as Detection Tools: Preparation, Characterization, and Biosensing Applications
Current Nanoscience Redox Sensitivity of Tyrosine Hydroxylase Activity and Expression in Dopaminergic Dysfunction
CNS & Neurological Disorders - Drug Targets Functional and Structural MRI Biomarkers to Detect Pre-Clinical Neurodegeneration
Current Alzheimer Research Risperidone Microemulsion for Transnasal Delivery: Pharmacodynamic and Pharmacokinetic Evaluation
Pharmaceutical Nanotechnology Avascular Necrosis of Humeral Trochlea: A Case Report of the Rare Condition
Current Medical Imaging Electrophysiological Assessment of Visual Function in Autism Spectrum Disorders
Neuroscience and Biomedical Engineering (Discontinued) Steroid Hormones and Sleep Regulation
Mini-Reviews in Medicinal Chemistry Comparison of the Effects of Contralaterally Controlled Functional Electrical Stimulation and Neuromuscular Electrical Stimulation on Upper Extremity Functions in Patients with Stroke
CNS & Neurological Disorders - Drug Targets Newer Approaches to the Discovery of Glitazones
Mini-Reviews in Organic Chemistry Human Embryonic Stem Cell Therapies for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Self-Assembly of Proteins and Peptides and their Applications in Bionanotechnology
Current Nanoscience What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews Psychotherapy Through Video Game to Target Illness Related Problematic Behaviors of Children with Brain Tumor
Current Medical Imaging Self-Assembled Superlattices from Colloidal TiO2 Nanorods
Current Nanoscience Non-invasive Cerebellar Stimulation in Cerebellar Disorders
CNS & Neurological Disorders - Drug Targets Mitochondrial and Plastid Functions as Antimalarial Drug Targets
Current Drug Targets - Infectious Disorders